Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in previously treated patients with severe haemophilia A-Reference-Cited by-同舟云学术

Individual thrombin generation and spontaneous bleeding rate during personalized prophylaxis with Nuwiq®(human-cl rhFVIII) in previously treated patients with severe haemophilia A

Published:2018-05-31 Issue:4 Volume:24 Page:619-627
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Dargaud Y.¹^ORCID,Negrier C.¹,Rusen L.²,Windyga J.³^ORCID,Georgiev P.⁴,Bichler J.⁵,Solomon C.⁵⁶,Knaub S.⁵,Lissitchkov T.⁷,Klamroth R.⁸

Affiliation:

1. Hopital Cardiologique Louis Pradel; University of Lyon; Lyon France

2. Sanador SRL; Bucharest Romania

3. Department of Disorders of Haemostasis and Internal Medicine; Institute of Haematology and Transfusion Medicine; Warsaw Poland

4. Clinic of Haematology; University Multiprofile Hospital for Active Treatment “Sveti Georgi” and Medical University; Plovdiv Bulgaria

5. Octapharma AG; Lachen Switzerland

6. Department of Anesthesiology; Perioperative Care and General Intensive Care; Salzburg University Hospital; Paracelsus Medical University; Salzburg Austria

7. Department of Clinical Haematology in Haemorrhagic Diathesis and Anaemia; Specialized Hospital for Active Treatment “Joan Pavel”; Sofia Bulgaria

8. Vivantes Klinikum im Friedrichshain; Berlin Germany

Funder

Octapharma

Bayer

Baxter International

Baxalta

Novo Nordisk

CSL Behring

LFB

Pfizer

LeoPharma